V P Bondarev

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/704562/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy. Acta Virologica, 2011, 55, 3-14.	0.8	7
2	Genome-Editing and Biomedical Cell Products: Current State, Safety and Efficacy. BIOpreparations Prevention Diagnosis Treatment, 2018, 18, 140-149.	0.5	5
3	Analysis of the mechanisms of development of the immune response in hepatitis B virus infection and ways to improve the effectiveness of vaccination. Immunologiya, 2021, 42, 403-414.	0.3	3
4	Rotavirus Epidemiology and Vaccination Tactics. BIOpreparations Prevention Diagnosis Treatment, 2019, 19, 81-87.	0.5	3
5	Epidemiological aspects of meningococcal infection and problems of vaccine prophylaxis. Infektsionnye Bolezni, 2016, 14, 55-64.	0.4	2
6	Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2019, 9, 41-48.	0.2	2
7	The Current Use of Biomedical Cell Products for Cancer Treatment. BlOpreparations Prevention Diagnosis Treatment, 2019, 19, 206-214.	0.5	2
8	Recommendations on the certification of reference standards for structure identification of recombinant therapeutic proteins. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 218-225.	0.5	2
9	Factor VIII products: key aspects of development, clinical research and use (part 1). BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 39-49.	0.5	1
10	General characteristics of adjuvants and their mechanisms of action (part 2). BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 20-30.	0.5	1
11	General Considerations on Clinical Trials of Hemophilia Medicines. BlOpreparations Prevention Diagnosis Treatment, 2020, 20, 30-41.	0.5	1
12	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 228-244.	0.5	1
13	Vaccine interchangeability: problems and prospects. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 142-157.	0.5	1
14	Critical Development Needs for Recombinant Blood-Coagulation Factors. Pharmaceutical Chemistry Journal, 2016, 50, 573-576.	0.8	0
15	Development of an Industrial Reference Sample for the Specific Activity of Erythropoietin. Pharmaceutical Chemistry Journal, 2018, 52, 90-94.	0.8	0
16	Comparative Analysis of Approaches to Assess the Quality of Inactivated Influenza Vaccines: Regulatory Requirements in the Russian Federation and European Union. Epidemiologiya I Vaktsinoprofilaktika, 2021, 19, 36-47.	0.8	0
17	Factor VIII products: key aspects of development, clinical research and use (part 2). BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 97-107.	0.5	0
18	Experimental study of biological and biomechanical compatibility of nanostructured spiral stent. Novosti Khirurgii, 2014, 22, 654-664.	0.2	0

V P Bondarev

#	Article	IF	CITATIONS
19	Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA. BIOpreparations Prevention Diagnosis Treatment, 2019, 19, 17-27.	0.5	0
20	Special Considerations on the Use of Vaccines for Immunoprophylaxis of Bacterial Infections. BIOpreparations Prevention Diagnosis Treatment, 2019, 19, 145-153.	0.5	0
21	Principles for clinical trials of coagulation factor IX products. Pacific Medical Journal, 2020, , 11-18.	0.3	Ο
22	Problems associated with the manifestation of immunogenicity of biotherapeutic proteins and ways to solve them. Immunologiya, 2021, 42, 706-719.	0.3	0
23	Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 234-243.	0.5	Ο
24	Promising opportunities to improve polio vaccines. BIOpreparations Prevention Diagnosis Treatment, 0, , .	0.5	0